RiverVest Venture Partners related stories
All articles and analysis
Biolinq attracts $100m Series BBiolinq Incorporated, a medical device company, has secured $100 million in Series B financing.
Sparrow Pharmaceuticals rings in $50m Series ASparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company, has raised $50 million in Series A financing.
- RiverVest Venture Partners raises $275m for fifth fund
RiverVest Venture Partners has closed its fifth fund at $275 million. The fund's limited partners include most major investors from earlier RiverVest funds and several new institutional investors.
- VC-backed Spruce Biosciences adds CFO and VP to team
San Francisco-based Spruce Biosciences, a developer of novel therapies for rare endocrine disorders, has named Samir Gharib as chief financial officer and Dr. Dasharatha Reddy as vice president of pharmaceutical development and manufacturing.
- Avalyn Pharma nets $35.5m Series B
Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing.
Adarza BioSystems garners $25 mn Series DSt. Louis, Missouri-based Adarza BioSystems, a biotech firm, has secured $25 million in Series D funding.
RiverVest adds MD and senior associate to teamRiverVest Venture Partners has named Derek Rapp as managing director and Dr. Isaac Zike as senior associate. Previously, Rapp was president and CEO of JDRF while Zike was a life sciences associate at Huron Consulting Group.
- VC-backed Mirum Pharmaceuticals debuts IPO
Foster City, California-based Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading July 18, 2019 on the NASDAQ under the ticker symbol "MIRM." Citigroup, Evercore ISI and Guggenheim Securities are the lead underwriters. Mirum's pre-IPO backers included NEA, Deerfield Management, Frazier Healthcare Partners, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.
- ScoutBio raises $20 mln
ScoutBio said April 10 that it raised $20 million in Series B financing co-led by Digitalis Ventures’ Companion Fund and RiverVest Venture Partners. GreenSpring Associates as well as existing investors Frazier Healthcare Partners, Adage Capital Management and Correlation Ventures participated in the round. ScoutBio is a biotech focused on pet medicine that aims to deliver a pipeline of one-time therapeutics for major chronic pet health conditions.
